<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504296</url>
  </required_header>
  <id_info>
    <org_study_id>I188</org_study_id>
    <secondary_id>CAN-NCIC-IND188</secondary_id>
    <secondary_id>S*BIO-SB939-2007-002</secondary_id>
    <secondary_id>CDR0000558934</secondary_id>
    <nct_id>NCT00504296</nct_id>
  </id_info>
  <brief_title>SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Clinical and Pharmacokinetic Study of SB939 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>S*BIO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating&#xD;
      patients with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the recommended phase II dose of oral SB939 in patients with solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the toxic effects of SB939 and its association with dose and&#xD;
           pharmacokinetics.&#xD;
&#xD;
        -  To assess the pharmacokinetic profile of SB939.&#xD;
&#xD;
        -  To assess preliminary evidence of antitumor effects of SB939 in patients with measurable&#xD;
           disease as documented by objective response.&#xD;
&#xD;
        -  To establish proof-of-principle for SB939 effects on histone acetylation by evaluation&#xD;
           of histone acetylation and other biomarkers in peripheral blood mononuclear cells&#xD;
           (PBMCs) at all dose levels.&#xD;
&#xD;
      OUTLINE: Patients receive oral SB939 once daily on days 1-5 and 15-19. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection periodically during course 1 for pharmacokinetic and&#xD;
      pharmacodynamic studies. Samples are analyzed for levels of SB939 via LC-MS/MS method and&#xD;
      levels of acetylated histone 3 (AcH3), target effect, downstream consequences, and tumor&#xD;
      response via western blot, immunohistochemistry, or ELISA methods.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2007</start_date>
  <completion_date type="Actual">June 21, 2011</completion_date>
  <primary_completion_date type="Actual">April 22, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose</measure>
    <time_frame>Each dose level</time_frame>
    <description>Assess for safety, tolerability, toxicity profile and dose limiting toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Each dose level</time_frame>
    <description>Safety, tolerability, toxicity profile, dose limiting toxicities of SB939.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>Cycle 1 day 1 and 15</time_frame>
    <description>Samples collected over multiple timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SB939 effects on histone H3 acetylation</measure>
    <time_frame>Cycle 1 days 1 and 15</time_frame>
    <description>Levels of AcH3 will be determined using wetern Blot, immunohistochemistry or Elisa method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>SB939</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDAC inhibitor SB939</intervention_name>
    <description>SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.</description>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced or metastatic solid tumor&#xD;
&#xD;
               -  Refractory to standard therapy or for which conventional therapy is not reliably&#xD;
                  effective&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with documented CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Must have a life expectancy of ≥ 12 weeks&#xD;
&#xD;
          -  Granulocytes (AGC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN (&lt; 5 x ULN if liver metastases are present)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.2 x ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  QTc ≤ 450 msec&#xD;
&#xD;
          -  LVEF ≥ 50% by ECHO or MUGA&#xD;
&#xD;
          -  Troponin I or T ≤ ULN&#xD;
&#xD;
          -  Must be within 1½ hour's driving distance&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pathologic cardiac arrhythmia requiring active treatment&#xD;
&#xD;
               -  Patients with a history of arrhythmia must be &gt; 12 months since last treatment&#xD;
                  with no recurrence of arrhythmia in the interval&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
               -  Patients must be able to swallow SB939 capsules and have no gastrointestinal&#xD;
                  abnormalities (e.g., bowel obstruction or previous gastric resection) which would&#xD;
                  lead to inadequate absorption of SB939&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
               -  Urine or serum B-HCG must be negative&#xD;
&#xD;
          -  Women or men of child-bearing potential unless using effective contraception&#xD;
&#xD;
          -  Presence of any clinically significant co-morbidities (i.e., pulmonary disease, active&#xD;
             CNS disease, or active infection)&#xD;
&#xD;
          -  Presence of any other significant CNS disorder that would hamper the patient's&#xD;
             compliance&#xD;
&#xD;
          -  Presence of any significant psychiatric disorder that would hamper the patient's&#xD;
             compliance&#xD;
&#xD;
          -  Other acute or chronic medical condition, psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risks associated with study participation/study drug&#xD;
             administration or may interfere with the interpretation of study results&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Known HIV or hepatitis B or C infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Previous anticancer treatment must be discontinued at least 28 days prior to the first&#xD;
             dose of study treatment (42 days [6 weeks] for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  At least 28 days since prior radiation therapy restricted to ≤ 30% of the bone marrow&#xD;
             and recovered from toxic effects&#xD;
&#xD;
               -  Exceptions may be made for low-dose nonmyelosuppressive radiotherapy&#xD;
&#xD;
          -  Must be ≥ 14 days since any major surgery&#xD;
&#xD;
          -  Pre-existing bisphosphonate or luteinizing hormone-releasing hormone (LHRH) analog&#xD;
             therapy (for men with hormone refractory prostate cancer) may be continued during&#xD;
             study participation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous treatment with a histone deacetylase (HDAC) inhibitor&#xD;
&#xD;
          -  Treatment with another investigational therapy within 28 days prior to study entry&#xD;
&#xD;
          -  Other concurrent anticancer treatment or investigational therapy&#xD;
&#xD;
          -  Concurrent agents with a known risk of Torsade de Pointes&#xD;
&#xD;
          -  Concurrent G-CSF, GM-CSF, or other hematopoietic growth factors may not be used as a&#xD;
             substitute for a scheduled dose reduction (may be used in the management of acute&#xD;
             toxicity)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian L. Siu, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 2011 Mar 1;104(5):756-62. doi: 10.1038/bjc.2011.13. Epub 2011 Feb 1.</citation>
    <PMID>21285985</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

